Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jun 19;397(10292):2385-2438.
doi: 10.1016/S0140-6736(21)00684-X. Epub 2021 May 16.

The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030

Birgit Vogel  1 , Monica Acevedo  2 , Yolande Appelman  3 , C Noel Bairey Merz  4 , Alaide Chieffo  5 , Gemma A Figtree  6 , Mayra Guerrero  7 , Vijay Kunadian  8 , Carolyn S P Lam  9 , Angela H E M Maas  10 , Anastasia S Mihailidou  11 , Agnieszka Olszanecka  12 , Jeanne E Poole  13 , Clara Saldarriaga  14 , Jacqueline Saw  15 , Liesl Zühlke  16 , Roxana Mehran  17
Affiliations
Review

The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030

Birgit Vogel et al. Lancet. .

Abstract

Cardiovascular disease is the leading cause of death in women. Decades of grassroots campaigns have helped to raise awareness about the impact of cardiovascular disease in women, and positive changes affecting women and their health have gained momentum. Despite these efforts, there has been stagnation in the overall reduction of cardiovascular disease burden for women in the past decade. Cardiovascular disease in women remains understudied, under-recognised, underdiagnosed, and undertreated. This Commission summarises existing evidence and identifies knowledge gaps in research, prevention, treatment, and access to care for women. Recommendations from an international team of experts and leaders in the field have been generated with a clear focus to reduce the global burden of cardiovascular disease in women by 2030. This Commission represents the first effort of its kind to connect stakeholders, to ignite global awareness of sex-related and gender-related disparities in cardiovascular disease, and to provide a springboard for future research.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests MA reports personal fees from Bayer, Boehringer, Tecnofarma, and Axon, and non-financial support from Boehringer, outside the submitted work. YA reports grants from the Dutch Heart Foundation and has a patent image guided plaque ablation (USP 945593 licenced). CNBM reports grants from US National Institutes of Health (NIH) Study Section, Peer Review Medical Research Program Cardiovascular Health for the Department of Defense Congressionally Directed Medical Research Program, US National Heart, Lung, and Blood Institute (NHLBI) subcontract to Research Triangle Institute International, NHLBI R01, US National Institute on Aging U54, and Women's Ischemia Syndrome Evaluation HFpEF; consulting fees from the US Food and Drug Administration Renal Advisory Panel; and consulting fees or honoraria from iRhythm, Abbott Diagnostics, and Sanofi Vascular. AC reports personal fees from Abbott Vascular, Magenta, Biosensor, Abiomed, and Cardional Health. GAF reports grants from the Australian National Health and Medical Research Council and Abbott Diagnostics; and personal fees from CSL Behring and Janssen. VK reports personal fees from honoraria and for speaking from Bayer, Daichii Sankyo, Amgen, AstraZeneca, and Abbott, outside the submitted work. CSPL reports grants from Boston Scientific, Bayer, Roche Diagnostics, AstraZeneca, Medtronic, and Vifor Pharma; personal fees from Abbott Diagnostics, Amgen, Applied Therapeutics, AstraZeneca, Bayer, Biofourmis, Boehringer Ingelheim, Boston Scientific, Corvia Medical, Cytokinetics, Darma, Us2.ai, JanaCare, Janssen Research & Development, Medtronic, Menarini Group, Merck, MyoKardia, Novartis, Novo Nordisk, Radcliffe Group, Roche Diagnostics, Sanofi, Stealth BioTherapeutics, The Corpus, Vifor Pharma, and WebMD Global; and has a patent pending (PCT/SG2016/050217), and a patent issued (16/216,929). JEP reports grants from BIOTRONIK and AtriCure. JS reports grants from the Canadian Institutes of Health Research, Heart & Stroke Foundation of Canada, Michael Smith Foundation of Health Research, and NIH; and consulting fees from Abbott Vascular, Boston Scientific, Gore, Baylis, and Abiomed. RM reports grants from Abbott Laboratories, Abiomed, Applied Therapeutics, AstraZeneca, Bayer, Beth Israel Deaconess, Bristol-Myers Squibb, Cerecor, Chiesi, Concept Medical, CSL Behring, DSI, Medtronic, Novartis Pharmaceuticals, OrbusNeich, and Zoll; personal fees from Boston Scientific, Cine-Med Research, Janssen Scientific Affairs, Medscape/WebMD, American College of Cardiology, and American Medical Association; non-financial support from Regeneron Pharmaceuticals; consultancy or advisory board fees paid to her institution from Abbott Laboratories, Beth Israel Deaconess, Bristol Myers Squibb, Chiesi, Concept Medical, Daiichi Sankyo, Medtronic, Novartis, CardiaWave, Duke University, Idorsia, Spectranetics/Philips/Volcano Corp; consultant fees paid to the institution of her spouse from Abiomed, Bayer; <1% equity in Applied Therapeutics, Elixir Medical, and STEL; and spouse's <1% equity in ControlRad. All other authors declare no competing interests.

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles